<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="195">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01382407</url>
  </required_header>
  <id_info>
    <org_study_id>B427CTIL</org_study_id>
    <nct_id>NCT01382407</nct_id>
  </id_info>
  <brief_title>Does Acne Rash During Adolescence Predict Skin Reaction to Cetuximab</brief_title>
  <official_title>Does Acne Rash During Adolescence Predict Skin Reaction to Cetuximab?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <authority>Israel: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of this study is that patients who suffered from acne vulgaris during
      adolescence are at greater risk of developing acneiform skin rash due to cetuximab.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hypothesis of this study is that patients who suffered from acne vulgaris during
      adolescence are at greater risk of developing acneiform skin rash due to cetuximab
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Relationship between acne and skin rash</measure>
    <time_frame>Within Erbitux treatment period (upto 12 months)</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine whether there is a relationship between acne during adolescence and skin rash during cetuximab treatment?</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Colorectal Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Cetuximab</arm_group_label>
    <description>All patients who started treatment with ERBITUX® (cetuximab), as a single agent or in combination with chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Once a week:Loading dose-400 mg/m2;subsequent-250 mg/m2 on days 8,15, 22,29,36 if administered as a single agent, or together with Irinotecan 125 mg/m2 on days 1,8,15,29 followed by administration every 42 days.</description>
    <arm_group_label>Cetuximab</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients above the age of 18 years, who have been diagnosed with confirmed KRAS-WT
        mCRC, and are starting treatment with cetuximab, will be informed of the study.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age above 18 years.

          -  Histology or cytology proven KRAS-WT mCRC.

          -  Performance status ≤3 (Eastern Cooperative Oncology Group [ECOG] classification)

          -  Life expectancy of more than 12 weeks.

          -  Written informed consent.

          -  In women of childbearing potential, appropriate contraceptive measures must be used
             during treatment with cetuximab and for 6 months following the last dose of
             cetuximab.

        Exclusion Criteria:

          -  Past systemic immune therapy for disease other than cancer.

          -  Past immune or other target therapy for cancer (not including bevacizumab).

          -  Presence of acne or acneiform rash prior to starting treatment with cetuximab.

          -  Patients with treatment plan of cetuximab and capecitabine combination.

          -  For female patients: the patient is pregnant or lactating.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gil Bar-Sela, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Health Care Campus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oncology Institute, Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <lastchanged_date>May 11, 2015</lastchanged_date>
  <firstreceived_date>June 23, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>skin rash reaction</keyword>
  <keyword>ERBITUX® (cetuximab)</keyword>
  <keyword>acne</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
